Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20250911-00646
Y M Jia
{"title":"[Old photos, deep feelings].","authors":"Y M Jia","doi":"10.3760/cma.j.cn112148-20250911-00646","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20250911-00646","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1199-1200"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20250721-00519
Y Wang, Y H Sun, Y Liu, J X Fan, Y Q Wang, Y X Jiang, H Wang, J M Yang, L Y Wang, S Y Guo, W Wang, Y Tian
Objective: To preliminarily evaluate the lumen gain of sonodynamic therapy (SDT) mediated by sinoporphyrin sodium at carotid and femoral atherosclerotic plaque sites, and to assess whether concomitant statin use, lesion location, plaque echogenicity/type, and baseline stenosis severity modify the therapeutic response. Methods: This single-center, prospective, exploratory pilot clinical study enrolled patients with peripheral artery disease who attended the outpatient cardiology clinic of the First Affiliated Hospital of Harbin Medical University between February and September 2016. All enrolled patients received optimized oral medical therapy in combination with a single session of SDT. Vascular evaluation was performed using color Doppler ultrasound before treatment and 1 and 4 weeks after treatment. The primary efficacy endpoint was the percent change from baseline in luminal diameter stenosis at the site of the atherosclerotic plaque (%Δ) at week 4, while the secondary efficacy endpoint was %Δ at week 1. Subgroup analyses were conducted according to prior statin use, plaque location, plaque characteristics, and baseline degree of luminal stenosis. Results: A total of 24 patients, aged (70.7±2.2) years were enrolled. There were 20 (83%) males. Compared to baseline, luminal diameter stenosis at the plaque site reduced by week 4 ((50.1±1.2)% vs. (57.2±1.1)%,P<0.001), %Δ was(12.32±1.05)%; and luminal diameter stenosis also reduced by week 1 ((51.7±1.2)% vs. (57.2±1.1)%,P<0.001)), %Δ was(9.61±0.85)%. In subgroup analyses, the treatment effect on diameter stenosis was independent of prior statin use; SDT reduced stenosis in both carotid and femoral plaques; with superior efficacy observed in hypoechoic and mixed-echo plaques; and efficacy was observed across mild, moderate, and severe baseline stenosis categories (all P<0.05). Conclusion: In this single-center pilot study, SDT demonstrates therapeutic efficacy across mild, moderate, and severe stenoses, as well as in hypoechoic and mixed-echo plaques, showing potential to rapidly promote luminal gain at carotid and femoral atherosclerotic plaque sites.
{"title":"[Sonodynamic therapy promotes luminal gain in carotid and femoral atherosclerotic plaques: a single-center prospective clinical study].","authors":"Y Wang, Y H Sun, Y Liu, J X Fan, Y Q Wang, Y X Jiang, H Wang, J M Yang, L Y Wang, S Y Guo, W Wang, Y Tian","doi":"10.3760/cma.j.cn112148-20250721-00519","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20250721-00519","url":null,"abstract":"<p><p><b>Objective:</b> To preliminarily evaluate the lumen gain of sonodynamic therapy (SDT) mediated by sinoporphyrin sodium at carotid and femoral atherosclerotic plaque sites, and to assess whether concomitant statin use, lesion location, plaque echogenicity/type, and baseline stenosis severity modify the therapeutic response. <b>Methods:</b> This single-center, prospective, exploratory pilot clinical study enrolled patients with peripheral artery disease who attended the outpatient cardiology clinic of the First Affiliated Hospital of Harbin Medical University between February and September 2016. All enrolled patients received optimized oral medical therapy in combination with a single session of SDT. Vascular evaluation was performed using color Doppler ultrasound before treatment and 1 and 4 weeks after treatment. The primary efficacy endpoint was the percent change from baseline in luminal diameter stenosis at the site of the atherosclerotic plaque (%Δ) at week 4, while the secondary efficacy endpoint was %Δ at week 1. Subgroup analyses were conducted according to prior statin use, plaque location, plaque characteristics, and baseline degree of luminal stenosis. <b>Results:</b> A total of 24 patients, aged (70.7±2.2) years were enrolled. There were 20 (83%) males. Compared to baseline, luminal diameter stenosis at the plaque site reduced by week 4 ((50.1±1.2)% vs. (57.2±1.1)%,<i>P</i><0.001), %Δ was(12.32±1.05)%; and luminal diameter stenosis also reduced by week 1 ((51.7±1.2)% vs. (57.2±1.1)%,<i>P</i><0.001)), %Δ was(9.61±0.85)%. In subgroup analyses, the treatment effect on diameter stenosis was independent of prior statin use; SDT reduced stenosis in both carotid and femoral plaques; with superior efficacy observed in hypoechoic and mixed-echo plaques; and efficacy was observed across mild, moderate, and severe baseline stenosis categories (all <i>P</i><0.05). <b>Conclusion:</b> In this single-center pilot study, SDT demonstrates therapeutic efficacy across mild, moderate, and severe stenoses, as well as in hypoechoic and mixed-echo plaques, showing potential to rapidly promote luminal gain at carotid and femoral atherosclerotic plaque sites.</p>","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1216-1224"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20251005-00693
Y M Qi, D X Zhou
{"title":"[Research progress on prediction models for pacemaker implantation after transcatheter aortic valve replacement].","authors":"Y M Qi, D X Zhou","doi":"10.3760/cma.j.cn112148-20251005-00693","DOIUrl":"10.3760/cma.j.cn112148-20251005-00693","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1287-1293"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20250715-00510
J Qian, Y Du, W Sha, S K Rong, Y Q Yao, R Hu, C M Deng, D C Liu, J L Du, Q She, B Yu, X P Chen, J Huang
Objective: To preliminarily evaluate the efficacy and safety of a domestically developed bilateral interventional ultrasound renal denervation (RDN) system in patients with uncontrolled hypertension despite antihypertensive medication. Methods: A multicenter, single-arm trial was conducted. Patients with uncontrolled hypertension (≥2 antihypertensive drugs) were enrolled from April 2023 to April 2024 at the Second Affiliated Hospital of Chongqing Medical University, West China Hospital of Sichuan University, and the Second Affiliated Hospital of Harbin Medical University. RDN was performed using the UltraCure™ bilateral interventional ultrasound system via femoral or brachial artery access. Multi-segmental "quadrant-based" ablation was performed in bilateral main renal arteries and branches/accessory arteries (diameter≥4 mm). Primary endpoints were changes in office systolic blood pressure (SBP) and 24-hour daytime SBP at 2-and 6-months post-procedure. The primary safety endpoints included the incidence of major adverse events, device-related adverse events, and puncture site complications. Results: Ten patients, mean aged 47.1 years, including 9 male, successfully completed RDN. At 2 and 6 months post-procedure, office SBP decreased by (19.7±15.2) mmHg (P=0.002, 1 mmHg=0.133 kPa) and (13.8±13.9) mmHg (P=0.013) from baseline, while the 24-hour daytime SBP decreased by (13.4±10.6) mmHg (P=0.004) and (11.2±9.2) mmHg (P=0.004). Apart from one case of a limited distal renal artery dissection, no other serious device/procedure-related adverse events were observed. At 6-month follow-up, the estimated glomerular filtration rate remained stable ((85.3±18.3) ml·min-1·1.73 m-2 vs. (82.3±19.2) ml·min-1·1.73 m-2, P=0.41). No renal artery stenosis was detected. Conclusions: The domestic interventional ultrasound RDN system could effectively reduce office and ambulatory blood pressure in patients with uncontrolled hypertension, demonstrating a favorable safety profile. Long-term efficacy requires confirmation through large-scale randomized controlled trials.
{"title":"[Phase Ⅰ clinical study of bilateral catheter-based ultrasound renal denervation in patients with uncontrolled hypertension].","authors":"J Qian, Y Du, W Sha, S K Rong, Y Q Yao, R Hu, C M Deng, D C Liu, J L Du, Q She, B Yu, X P Chen, J Huang","doi":"10.3760/cma.j.cn112148-20250715-00510","DOIUrl":"10.3760/cma.j.cn112148-20250715-00510","url":null,"abstract":"<p><p><b>Objective:</b> To preliminarily evaluate the efficacy and safety of a domestically developed bilateral interventional ultrasound renal denervation (RDN) system in patients with uncontrolled hypertension despite antihypertensive medication. <b>Methods:</b> A multicenter, single-arm trial was conducted. Patients with uncontrolled hypertension (≥2 antihypertensive drugs) were enrolled from April 2023 to April 2024 at the Second Affiliated Hospital of Chongqing Medical University, West China Hospital of Sichuan University, and the Second Affiliated Hospital of Harbin Medical University. RDN was performed using the UltraCure™ bilateral interventional ultrasound system via femoral or brachial artery access. Multi-segmental \"quadrant-based\" ablation was performed in bilateral main renal arteries and branches/accessory arteries (diameter≥4 mm). Primary endpoints were changes in office systolic blood pressure (SBP) and 24-hour daytime SBP at 2-and 6-months post-procedure. The primary safety endpoints included the incidence of major adverse events, device-related adverse events, and puncture site complications. <b>Results:</b> Ten patients, mean aged 47.1 years, including 9 male, successfully completed RDN. At 2 and 6 months post-procedure, office SBP decreased by (19.7±15.2) mmHg (<i>P</i>=0.002, 1 mmHg=0.133 kPa) and (13.8±13.9) mmHg (<i>P</i>=0.013) from baseline, while the 24-hour daytime SBP decreased by (13.4±10.6) mmHg (<i>P</i>=0.004) and (11.2±9.2) mmHg (<i>P</i>=0.004). Apart from one case of a limited distal renal artery dissection, no other serious device/procedure-related adverse events were observed. At 6-month follow-up, the estimated glomerular filtration rate remained stable ((85.3±18.3) ml·min<sup>-1</sup>·1.73 m<sup>-2</sup> vs. (82.3±19.2) ml·min<sup>-1</sup>·1.73 m<sup>-2</sup>, <i>P</i>=0.41). No renal artery stenosis was detected. <b>Conclusions:</b> The domestic interventional ultrasound RDN system could effectively reduce office and ambulatory blood pressure in patients with uncontrolled hypertension, demonstrating a favorable safety profile. Long-term efficacy requires confirmation through large-scale randomized controlled trials.</p>","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1225-1230"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20241216-00787
Y J Sun, X Y Zhang, Y Hu, Z W Lin, J Xiao, P Li, X Zhao, H F Zhang, B Qin, D Q Jia, T Zhang, J Ma, H P Chen, C J Zhang, X W Geng, K Y Zhang, M Zheng, F L Zhang, Y Lang, H G Hou, P Liu, H F Jia, J J Lu, K Zhao, H Zhao, J C Xu, M Zhang, X X Li, D X Zhang, L Zhong, H Zhao, F F Liu, Y Liu, D X Miao, C W Wang, H Zhang, C Wang, F Wang, X J Zhang, H X Lyu, X P Ji
<p><p><b>Objective:</b> To explore the impact of the two-way referral model on compliance and prognosis in patients with heart failure. <b>Methods:</b> This bidirectional cohort study enrolled chronic heart failure (CHF) patients treated at Qilu Hospital of Shandong University or designated primary hospitals between March 2018 and March 2022. Patients were categorized into two groups based on referral status: two-way referral group (participating in the referral model with≥1 follow-up visit at primary hospitals) and the core hospital group (receiving treatment and follow-up exclusively at Qilu Hospital). Baseline clinical characteristics were collected and compared between groups. Patients underwent followed-up, with primary endpoints including follow-up rate, drug (β-blockers, angiotension converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists) utilization rate and target dose achievement rate. Secondary endpoints encompassed changes from baseline in left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDd), and N-terminal pro-brain natriuretic peptide (NT-proBNP), plus cardiovascular mortality and heart failure rehospitalization. Generalized linear mixed models analyzed longitudinal trends in LVEF, LVEDd, and NT-proBNP levels. Kaplan-Meier curves and Cox regression evaluated LVEF recovery rates, supplemented by subgroup analyses. Multivariate logistic regression was used to identify factors influencing target dose achievement rate for β-blockers and ACEI/ARB/ARNI therapies in CHF patients. <b>Results:</b> A total of 357 patients were enrolled, aged 53 (41, 63) years, including 256 males (71.7%). 157 patients were in the two-way referral group and 200 patients in the core hospital-treated group. Compared with the core hospital-treated group, the two-way referral group had lower baseline LVEF (28 (22, 34)% vs. 31 (23, 36)%, <i>P</i>=0.021) and systolic blood pressure (116 (104, 125) mmHg vs. 121 (109, 134) mmHg (1 mmHg=0.133 kPa), <i>P</i>=0.010). The 12-month follow-up rate of the two-way referral group was higher than the core hospital-treated group (73.8% vs. 56.0%, <i>P</i>=0.004). No significant between-group differences were observed in drug utilization rate of β-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all <i>P</i>>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups. Although the core hospital-treated group had higher target dose achievement rates for β-blockers (65.4% vs. 49.3%, <i>P</i>=0.042) and ACEI/ARB/ARNI (79.8% vs. 65.8%, <i>P</i>=0.046) than the two-way referral group, multivariate logistic regression indicated that the two-way referral model was not a negative predictor for these outcomes (all <i>P</i>>0.05). Both groups showed improved NT-proBNP, LVEDd, an
目的：探讨双向转诊模式对心衰患者依从性及预后的影响。方法：本研究选取了2018年3月至2022年3月在山东大学齐鲁医院或指定基层医院治疗的慢性心力衰竭（CHF）患者。根据转诊情况将患者分为两组：双向转诊组（参与转诊模式，在基层医院随访≥1次）和核心医院组（仅在齐鲁医院接受治疗和随访）。收集基线临床特征并比较两组间的差异。对患者进行随访，主要终点包括随访率、药物(β受体阻滞剂、血管紧张素转换酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂（ARB)/血管紧张素受体-neprilysin抑制剂（ARNI）、钠-葡萄糖共转运蛋白2抑制剂和矿皮质激素受体拮抗剂）使用率和靶剂量成成率。次要终点包括左室射血分数（LVEF）、左室舒张末期内径（LVEDd）和n端脑利钠肽前体（NT-proBNP）与基线相比的变化，以及心血管死亡率和心力衰竭再住院率。广义线性混合模型分析了LVEF、LVEDd和NT-proBNP水平的纵向趋势。Kaplan-Meier曲线和Cox回归评估LVEF的恢复率，并辅以亚组分析。采用多因素logistic回归分析确定影响β受体阻滞剂和ACEI/ARB/ARNI治疗CHF患者靶剂量成成率的因素。结果：共纳入357例患者，年龄53（41,63）岁，其中男性256例（71.7%）。157例患者在双向转诊组，200例患者在核心医院治疗组。与核心医院治疗组相比，双向转诊组的基线LVEF(28（22,34)%比31 (23,36)%，P=0.021）和收缩压(116 (104,125)mmHg比121 （100,134)mmHg (1mmhg =0.133 kPa)， P=0.010）较低。双向转诊组12个月随访率高于核心住院治疗组（73.8% vs. 56.0%， P=0.004）。随访期间，β受体阻滞剂、ACEI/ARB/ARNI、钠-葡萄糖共转运蛋白2抑制剂的药物使用率组间差异无统计学意义（P < 0.05），而矿皮质激素受体拮抗剂的使用率组间均呈下降趋势。虽然核心医院治疗组β受体阻滞剂的靶剂量达标率（65.4%比49.3%，P=0.042）和ACEI/ARB/ARNI（79.8%比65.8%，P=0.046）高于双向转诊组，但多因素logistic回归显示，双向转诊模型对这些结果并不是负向预测因子（P均为0.05）。两组的NT-proBNP、LVEDd和LVEF均较基线有所改善（p < 0.05）。两组12个月心血管死亡和心力衰竭再住院的综合发生率（7.6% vs 6.5%， P=0.674）和累积发生率（log-rank P=0.684）差异无统计学意义。结论：双向转诊模式在提高心力衰竭患者的服药依从性、药物使用率和目标剂量达标率方面具有优势。该模型不仅促进心功能恢复，还降低了心血管死亡和心力衰竭再住院的风险，实现了与核心医院治疗患者相当的治疗和管理结果。
{"title":"[The influence of two-way referral model on treatment and prognosis of patients with chronic heart failure].","authors":"Y J Sun, X Y Zhang, Y Hu, Z W Lin, J Xiao, P Li, X Zhao, H F Zhang, B Qin, D Q Jia, T Zhang, J Ma, H P Chen, C J Zhang, X W Geng, K Y Zhang, M Zheng, F L Zhang, Y Lang, H G Hou, P Liu, H F Jia, J J Lu, K Zhao, H Zhao, J C Xu, M Zhang, X X Li, D X Zhang, L Zhong, H Zhao, F F Liu, Y Liu, D X Miao, C W Wang, H Zhang, C Wang, F Wang, X J Zhang, H X Lyu, X P Ji","doi":"10.3760/cma.j.cn112148-20241216-00787","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20241216-00787","url":null,"abstract":"<p><p><b>Objective:</b> To explore the impact of the two-way referral model on compliance and prognosis in patients with heart failure. <b>Methods:</b> This bidirectional cohort study enrolled chronic heart failure (CHF) patients treated at Qilu Hospital of Shandong University or designated primary hospitals between March 2018 and March 2022. Patients were categorized into two groups based on referral status: two-way referral group (participating in the referral model with≥1 follow-up visit at primary hospitals) and the core hospital group (receiving treatment and follow-up exclusively at Qilu Hospital). Baseline clinical characteristics were collected and compared between groups. Patients underwent followed-up, with primary endpoints including follow-up rate, drug (β-blockers, angiotension converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists) utilization rate and target dose achievement rate. Secondary endpoints encompassed changes from baseline in left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDd), and N-terminal pro-brain natriuretic peptide (NT-proBNP), plus cardiovascular mortality and heart failure rehospitalization. Generalized linear mixed models analyzed longitudinal trends in LVEF, LVEDd, and NT-proBNP levels. Kaplan-Meier curves and Cox regression evaluated LVEF recovery rates, supplemented by subgroup analyses. Multivariate logistic regression was used to identify factors influencing target dose achievement rate for β-blockers and ACEI/ARB/ARNI therapies in CHF patients. <b>Results:</b> A total of 357 patients were enrolled, aged 53 (41, 63) years, including 256 males (71.7%). 157 patients were in the two-way referral group and 200 patients in the core hospital-treated group. Compared with the core hospital-treated group, the two-way referral group had lower baseline LVEF (28 (22, 34)% vs. 31 (23, 36)%, <i>P</i>=0.021) and systolic blood pressure (116 (104, 125) mmHg vs. 121 (109, 134) mmHg (1 mmHg=0.133 kPa), <i>P</i>=0.010). The 12-month follow-up rate of the two-way referral group was higher than the core hospital-treated group (73.8% vs. 56.0%, <i>P</i>=0.004). No significant between-group differences were observed in drug utilization rate of β-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all <i>P</i>>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups. Although the core hospital-treated group had higher target dose achievement rates for β-blockers (65.4% vs. 49.3%, <i>P</i>=0.042) and ACEI/ARB/ARNI (79.8% vs. 65.8%, <i>P</i>=0.046) than the two-way referral group, multivariate logistic regression indicated that the two-way referral model was not a negative predictor for these outcomes (all <i>P</i>>0.05). Both groups showed improved NT-proBNP, LVEDd, an","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1244-1253"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145596927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20250605-00417
Y Zeng, O Y Chen, S N Yong, S Z Wang
{"title":"[Macrophages and hypertensive cardiac remodeling].","authors":"Y Zeng, O Y Chen, S N Yong, S Z Wang","doi":"10.3760/cma.j.cn112148-20250605-00417","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20250605-00417","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1306-1310"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20250924-00674
T T Zhang, Z L Wang, X X Wang, Y F Guo
{"title":"[Cuprotosis and cardiovascular diseases].","authors":"T T Zhang, Z L Wang, X X Wang, Y F Guo","doi":"10.3760/cma.j.cn112148-20250924-00674","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20250924-00674","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1294-1299"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20251001-00688
T H Zhang, Y Du, X L Gao, L Xu, Y J Zhou
{"title":"[Research progress on pericoronary fat attenuation index].","authors":"T H Zhang, Y Du, X L Gao, L Xu, Y J Zhou","doi":"10.3760/cma.j.cn112148-20251001-00688","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20251001-00688","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1282-1286"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20250916-00655
J J Li, D Zhao
{"title":"[Introduction and interpretation of \"2025 focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias\"].","authors":"J J Li, D Zhao","doi":"10.3760/cma.j.cn112148-20250916-00655","DOIUrl":"10.3760/cma.j.cn112148-20250916-00655","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1278-1281"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.3760/cma.j.cn112148-20250715-00508
J Huang, S K Rong, J Qian, B Xiong, Y Q Yao, J L Du, Q She
{"title":"[Extracorporeal focused ultrasound targeted renal denervation].","authors":"J Huang, S K Rong, J Qian, B Xiong, Y Q Yao, J L Du, Q She","doi":"10.3760/cma.j.cn112148-20250715-00508","DOIUrl":"10.3760/cma.j.cn112148-20250715-00508","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"53 11","pages":"1212-1215"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号